Can Biktarvy be used to block infection in high-risk groups?

Biktarvy is a three-in-one oral antiHIV drug, consisting of bictegravir (Bictegravir), tenofovir alafenamide fumarate (TAF) and emtricitabine (Emtricitabine) and is mainly used to treat HIV-1 infected adults and adolescent patients. As a therapeutic drug, it has the advantages of strong virus suppression effect, convenient administration, and good tolerance. It is currently one of the commonly used first-line antiviral regimens. However, as to whether preventive blockade (PrEP) can be used for HIV high-risk groups, its scope of indications needs to be clearly distinguished.

Currently, Bitovil is not officially approved for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP). Mainstream drugs used for PrEP are usually combinations containing emtricitabine and tenofovir, such as Truvada (emtricitabine). span>+TDF) or Descovy (emtricitabine+TAF, only available in certain populations). Although the ingredients in Bituvit partially overlap with the drugs used in the PrEP regimen, it is not recommended for preventive use due to a lack of sufficient clinical research and official approval.

In addition, although the active ingredients in Bituvail theoretically have the ability to prevent HIV replication, without the support of relevant exposure prevention clinical data, there are potential risks in using it for preventive purposes in high-risk groups, including problems such as adverse reactions, drug resistance risks, and drug abuse. Therefore, if high-risk groups need HIV pre-exposure or post-exposure prophylaxis, they should still choose approved drugs with clear guidance and use them under the guidance of professional doctors.

In short, the current indication of Bitovil is to treat HIV infection, not to block infection or prevent HIV transmission. If high-risk groups want to take prevention through drugs, they should choose the approved PrEP drugs and carry out HIVScreening and medical evaluation are required before deciding whether to take medication. Never self-administer therapeutic medications as a preventive measure to avoid unnecessary medical risks.

Reference materials:https://www.biktarvy.com/